# Achim Berthele

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/achim-berthele/

## Facts

| Field | Value |
| --- | --- |
| Citations | 22,460 |
| Field | Multiple Sclerosis Research Studies |
| h-index | 65 |
| i10-index | 173 |
| Last Known Institution | TUM Klinikum |
| OpenAlex ID | https://openalex.org/A5018300417 |
| ORCID iD | https://orcid.org/0000-0001-9650-6222 |
| Works | 373 |

## Researcher papers

- [Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis](https://scholariq.org/papers/genetic-risk-and-a-primary-role-for-cell-mediated-immune-mechanisms-in-multiple/)
- [Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis](https://scholariq.org/papers/analysis-of-immune-related-loci-identifies-48-new-susceptibility-variants-for/)
- [Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility](https://scholariq.org/papers/multiple-sclerosis-genomic-map-implicates-peripheral-immune-cells-and-microglia/)
- [Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study](https://scholariq.org/papers/siponimod-versus-placebo-in-secondary-progressive-multiple-sclerosis-expand-a/)
- [Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients](https://scholariq.org/papers/contrasting-disease-patterns-in-seropositive-and-seronegative-neuromyelitis/)
- [Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)](https://scholariq.org/papers/update-on-the-diagnosis-and-treatment-of-neuromyelitis-optica-recommendations-of/)
- [Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management](https://scholariq.org/papers/update-on-the-diagnosis-and-treatment-of-neuromyelitis-optica-spectrum-disorders/)
- [Locus for severity implicates CNS resilience in progression of multiple sclerosis](https://scholariq.org/papers/locus-for-severity-implicates-cns-resilience-in-progression-of-multiple/)
- [Apheresis therapies for NMOSD attacks](https://scholariq.org/papers/apheresis-therapies-for-nmosd-attacks/)
- [Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis](https://scholariq.org/papers/update-on-the-diagnosis-and-treatment-of-neuromyelits-optica-spectrum-disorders/)

## Researcher topics

- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Peripheral Neuropathies and Disorders](https://scholariq.org/topics/peripheral-neuropathies-and-disorders/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Pain Mechanisms and Treatments](https://scholariq.org/topics/pain-mechanisms-and-treatments/)
- [Neuroscience and Neuropharmacology Research](https://scholariq.org/topics/neuroscience-and-neuropharmacology-research/)

## Researcher university

- [TUM Klinikum](https://scholariq.org/institutions/tum-klinikum/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.